相关实验视频
Updated: Jul 12, 2025

09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
2.7K
抗血小板剂 由于脑内出血导致的中风后使用
Rustam Al-Shahi Salman1, Steven M Greenberg2
1The University of Edinburgh, Royal Infirmary of Edinburgh, United Kingdom (R.A.-S.S.).
Stroke
|November 2, 2023
概括
在脑内出血 (ICH) 后,可以考虑使用抗血小板药物. RESTART试验表明,它们可能不会增加复发性ICH风险,但需要像ASPIRING这样的更大规模研究才能得到明确的答案.
科学领域:
- 神经学和心血管医学.
- 临床试验研究 临床试验研究
- 药理干预药理干预
背景情况:
- 脑内出血 (ICH) 幸存者面临重大心血管不良事件 (MACE) 的高风险.
- 抗血小板药物减少非ICH人群中的MACE,但可能增加ICH风险.
- 以前的指导依赖于风险-收益估计,因为ICH后证据有限.
研究的目的:
- 确定抗血小板药物对幸存者的MACE和复发性ICH的影响.
- 评估抗血小板治疗在ICH幸存者的特定亚组中的有效性和安全性.
- 为临床决策提供关于ICH后二次预防的强有力的证据.
主要方法:
- 该ASPIRING (脑内出血后抗血小板二次预防国际随机研究) 试验旨在招募4148名ICH幸存者.
- 这项大规模的随机对照试验将比较抗血小板治疗与避免治疗.
- 从RESTART试验 (537名参与者) 和三个较小的试验 (174名参与者) 的先前数据不足以得出最终的结论.
主要成果:
- RESTART试验 (2019年) 表明抗血小板药物可能不会增加与避免相比复发性ICH风险 (4% vs. 9%,调整HR0.51).
- 然而,证据水平被归类为B,表明需要进一步研究.
- 现有的试验不足以可靠地评估对所有MACE的影响.
结论:
- 目前的指导方针建议在ICH后可以考虑使用抗血小板药物,特别是如果与抗血小板药物使用相关.
- 该ASPIRING试验旨在提供关于抗血小板药物在ICH后的临床净益处的最终证据.
- 来自ASPIRING的结果将为未来的临床实践和ICH幸存者的二次预防指南提供信息.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
535
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
535
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Formation of the Platelet Plug
6.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
719
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
719
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11

